Ampullary and pancreatic adenocarcinoma-a comparative study

Area of Science:

• Gastrointestinal oncology
• Cancer genomics
• Molecular diagnostics

Background:

• Pancreatic ductal adenocarcinoma (PDAC) and ampullary adenocarcinoma (AAC) share symptoms but have distinct characteristics.
• AAC classification into pancreatobiliary (PB), intestinal (IT), and mixed (M) subtypes is critical for patient management.
• PB subtype pathogenesis may resemble PDAC, warranting comparative analysis.

Purpose of the Study:

• To compare the mutational status of KRAS, NRAS, and BRAF oncogenes in PDAC and AAC, focusing on the PB subtype.
• To enhance understanding of AAC biology through comparative genomic analysis.
• To identify potential differences in oncogene mutations between PDAC and AAC (PB subtype).

Main Methods:

• Pyrosequencing was used to analyze nine hot spot mutation sites in KRAS, NRAS, and BRAF.
• The study included 39 PDAC and 21 AAC samples from Tunisian patients.
• Comparative statistical analysis was performed using SPSS software.

Main Results:

• Mutations were found in 43% of AAC (47% in PB subtype) and 95% of PDAC, with KRAS being the most frequently mutated.
• Significant differences were observed between PDAC and AAC in tumor differentiation, invasion, staging, and mutational status.
• Significant differences were also noted when comparing PDAC and the PB subtype of AAC in tumor size, differentiation, invasion, staging, and mutational status.

Conclusions:

• Ampullary adenocarcinoma, including the PB subtype, is molecularly distinct from pancreatic ductal adenocarcinoma.
• Individualized therapy guided by histomolecular characteristics is recommended for these distinct tumor types.
• AAC and PDAC should not be diagnosed or treated as a single entity.